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Class 3 mutations in B-Raf proto-oncogene, Ser/Thr kinase
(BRAF), that result in kinase-impaired or kinase-dead BRAF
have the highest mutation frequency in BRAF gene in lung
adenocarcinoma. Several studies have reported that kinasedead BRAF variants amplify mitogen-activated protein kinase
(MAPK) signaling by dimerizing with and activating WT C-Raf
proto-oncogene, Ser/Thr kinase (CRAF). However, the structural and functional principles underlying their activation
remain elusive. Herein, using cell biology and various biochemical approaches, we established that variant BRAFD594G, a
kinase-dead representative of class 3 mutation-derived BRAF
variants, has a higher dimerization potential as compared with
WT BRAF. Molecular dynamics simulations uncovered that the
D594G substitution orients the ␣C-helix toward the IN position
and extends the activation loop within the kinase domain, shifting the equilibrium toward the active, dimeric conformation,
thus priming BRAFD594G as an effective allosteric activator of
CRAF. We found that B/CRAF heterodimers are the most thermodynamically stable RAF dimers, suggesting that RAF heterodimers, and not homodimers, are the major players in determining the amplitude of MAPK signaling in cells. Additionally,
we show that BRAFD594G:CRAF heterodimers bypass autoinhibitory P-loop phosphorylation, which might contribute to
longer duration of MAPK pathway signaling in cancer cells.
Last, we propose that the dimer interface of the BRAFD594G:
CRAF heterodimer may represent a promising target in the
design of novel anticancer therapeutics.

The mitogen-activated protein kinase (MAPK)2 pathway is
important in regulating cell proliferation and survival. The
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duration and amplitude of MAPK signaling are mainly controlled by the RAF Ser/Thr kinase family (ARAF, BRAF, and
CRAF), that contain three conserved regions (CR) for membrane recruitment (CR1), N-terminal 14-3-3 regulation (CR2),
and catalysis (CR3) (1). Among the three RAF isoforms, BRAF
has the highest basal activity and is most frequently mutated in
7– 8% of all human cancers (2). The high mutation propensity
in cancer led to extensive interest in the development of BRAFspecific drugs.
WT BRAF requires RAS-initiated membrane recruitment
and homo- or heterodimerization with other RAF isoforms
for activation. Although all BRAF mutations trigger constitutive activation of MAPK signaling in cancer cells, they have
distinct activation mechanisms and have been grouped into
three main classes to reflect different biochemical properties:
RAS- and dimer-independent (class 1), RAS-independent but
dimer-dependent (class 2), and RAS- and dimer-dependent
(class 3) (3). Class 1 mutations include the most common BRAF
mutation, V600E, which accounts for ⬃90% of all BRAF mutations (2). The prominence of BRAFV600E led to Food and Drug
Administration (FDA) approval of two ATP-competitive drugs,
vemurafenib and dabrafenib (4). These ATP-competitive drugs
elicit effective clinical outcomes for melanoma patients carrying the V600E mutation; however, paradoxical activation and
drug resistance restrict their application to cancers driven by
class 2 and 3 BRAF mutations (3, 5, 6).
Inactivating BRAF mutations, class 3, are currently the most
common BRAF mutation in lung adenocarcinoma (7). Herein,
we study a representative of class 3 BRAF mutations,
BRAFD594G, which is the most frequent kinase-dead mutation.
Asp-594 is part of the highly conserved DFG motif found in all
kinases. The aliphatic residues Phe/Gly help to maintain the
closed inactive conformation by occupying the ATP binding
pocket, whereas the Asp residue is a key catalytic residue
involved in Mg2⫹ coordination for the phospho-transfer reaction. Therefore, the mutation of Asp-594 to Gly prevents Mg2⫹
coordination, rendering BRAF catalytically inactive.
Intriguingly, the “kinase-dead” BRAF mutation has been validated as a driver of lung carcinoma (8, 9), suggesting that BRAF
has functions that are not limited to catalyzing MEK phosphorylation but extend to other roles that are independent of
enzyme activity. In parallel, the FDA-approved BRAF inhibitors
inhibit the catalytic activity of WT BRAF while boosting the
um; PEI-MAX, polyethyleneimine hydrochloride-MAX; ERK, extracellular
signal-regulated kinase; MBP, maltose-binding protein.
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noncatalytic function of BRAF to further up-regulate the
MAPK signaling, which leads to secondary malignancies in
clinic (5, 6, 10). This phenomenon, known as “paradoxical activation,” is a major concern surrounding current BRAF inhibitors. Apparently, ATP-competitive inhibitors rearrange the
structural elements of BRAF kinase to augment the noncatalytic functions, resulting in fundamentally different biological
outcomes. Our current view of RAF regulation is mainly
derived from mechanistic studies of enzymatically active RAF
kinases by evaluating their catalytic capability. The biochemistry of noncatalytic BRAF functions is poorly understood.
The unknown noncatalytic behavior of BRAF generates therapeutic limitations of ATP-competitive RAF drugs, including
paradoxical activation and drug resistance. It remains a
challenge to directly target kinase-dead BRAF mutants with
traditional ATP-competitive inhibitors. Novel approaches are
urgently needed. Here, we integrate biophysical, biochemical,
and computational approaches together with cellular assays to
explore the noncatalytic function of BRAF in cancer. Additionally, our study sheds light on the activation and regulation
mechanism of RAF kinase family under physiological and pharmacological conditions.

Results
BRAFD594G is more prone to dimerization than WT BRAF
Dimerization through the kinase domain is required for WT
BRAF and non-Val-600 BRAF mutations to function in normal
and cancerous cells (8, 11). Previously, Heidorn et al. (12) have
shown that kinase-dead BRAFD594A dimerizes with CRAF
when transiently transfected into D04 NRASQ61L cancer cells,
and Yao et al. (8) determined that BRAFD594G has a stronger
binding potential than WT BRAF to RAS. To complement the
previous cellular studies, we examined how this mutation
affects the biochemical properties of BRAF in its purified form.
Thus, we purified the catalytic domain (CD) of BRAFD594G
from Escherichia coli through affinity and size-exclusion chromatography with a purity of ⬎90% suitable for biophysical analyses (Fig. 1A). CD-BRAFD594G was subjected to velocity analytical ultracentrifugation (AUC) to determine the mass of
macromolecules in solution. The majority of our protein sedimented with a sedimentation coefficient (s) of ⬃3.8 S, which
relates to dimeric BRAF identified previously by Grasso et al.
(13) (Fig. 1B). WT CD-BRAF and a small population of
CD-BRAFD594G exist at ⬃2.6 s, which relates to monomeric
BRAF, previously identified by our laboratory and others (Fig.
1B) (13–15).
Next, we conducted molecular dynamics (MD) simulations
on monomeric and dimeric WT BRAF and monomeric
BRAFD594G to elucidate the structural basis for enhanced
dimerization. The starting structures are WT monomeric (PDB
entry 4WO5 (14)) and dimeric (PDB entry 4E26 (16)) kinase
domain, respectively. The BRAFD594G initial structure is constructed by mutating the WT monomer crystal structure (PDB
entry 4WO5 (14). The inhibitors in the crystal structure were
removed. We did not include ATP molecules, because
BRAFD594G mutation disables ATP binding (Fig. S1). One hallmark of BRAF activation is the movement of the ␣C-helix, with
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respect to orientation toward the C-lobe, from OUT (inactive)
to IN (active) conformation. The production runs of the simulations were carried out for 200 – 400 ns. The distances between
the center of masses of the ␣C-helix and the C-lobe were measured as on average 30 ⫾ 0.44, 28.5 ⫾ 0.45, and 25.6 ⫾ 0.30 Å,
for monomeric BRAFWT, monomeric BRAFD594G, and dimeric
BRAFWT, respectively. This emphasizes that the ␣C-helix of
monomeric BRAFD594G is closer to the C-lobe than the monomeric WT counterpart (Fig. 1, C and D). In the ␣C-helix-IN
conformation, residues in the ␣C-helix stabilize RAF dimers
through hydrophobic interactions (Arg-509 with Trp-450) and
H-bonds (Arg-509 with Thr-508/Arg-506/Leu-505). Our previous MD simulations together with structures of monomeric
BRAF kinase domain support that a fully extended activation
loop stabilizes active BRAF, whereas a rigid secondary-structure element, termed helix AS-H1, maintains an inactive
conformation of BRAF (14, 17). The possibility of forming secondary structures, including 310 helix and ␣-helix, were summarized in Table 1. The MD simulations show that the activation loop of BRAFD594G is in a transition between the AS-H1
and extended loop, which is supported by the loss of
the ␣-helical structure of the activation loop, whereas aa 598 –
600 form a short 310 helix (Fig. 1 (D and E) and Table 1). The
formation of the 310 helix is a product of the torsional strain
placed on the N terminus of the activation loop as the C terminus unwinds.
Together, these observations support that monomeric
CD-BRAFD594G adopts a partially active conformation indicating higher dimerization potential than CD-BRAFWT, as demonstrated by the AUC data (Fig. 1D). Additionally, adopting the
partially activated state instead of fully activated state minimizes BRAFD594G homodimerization that occurs when the
␣C-helix and activation loop are fully IN and extended, as evidenced by oncogenic BRAFV600E (17).
Dimerization potential correlates with the kinase activity of
RAF dimers
It was previously established that BRAF:CRAF heterodimers
are the most active RAF dimers in vitro (15). It remains elusive
how this translates to ERK hyperactivation by BRAFD594G:
CRAF. In light of this, we transfected CRAF alone or co-transfected BRAF:CRAF or BRAFD594G:CRAF into HEK293T cells
and immunoprecipitated MBP-tagged CRAF using amylose
resin to obtain either CRAF alone or BRAF:CRAF and
BRAFD594G:CRAF heterodimers, respectively. We added the
MBP tag to enhance the solubility of CRAF for our in vitro
experiments. The heterodimers have much higher activity than
CRAF in cells and in vitro (Fig. 2, A and B). The activity of
BRAFD594G:CRAF is comparable with that of BRAF:CRAF.
Thus, the kinase activity of BRAF is dispensable for transactivation of CRAF. Additionally, the observed high kinase activity
rules out the possibility of forming stable RAF homodimers, as
both BRAFD594G and CRAF homodimers have no or very minimal kinase activity. This is consistent with our previous studies
on BRAF:CRAF heterodimers, which demonstrated that separately purified BRAF and CRAF homodimers form stable
BRAF:CRAF heterodimers after mixing in vitro (15).
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Figure 1. Catalytic domain of BRAFD594G has increased dimerization in solution as compared with its WT counterpart. A, CD-BRAFD594G was purified and
analyzed by Coomassie Blue–stained SDS-PAGE. The molecular weight marker (M) and CD-BRAFD594G are identified above the gel. B, purified CD-BRAFD594G and
WT CD-BRAF were investigated using velocity AUC. Monomeric BRAF or dimeric BRAF is labeled above the image at ⬃2.5 or ⬃4 s, respectively. C, molecular
dynamics trajectory signifying the center of mass distance from the ␣C-helix toward the C-lobe as a function of simulation time are shown for monomeric WT
CD-BRAF (violet), monomeric CD-BRAFD594G (green), and dimeric WT CD-BRAF (blue). D, overlay of the representative snapshot from the MD simulations for
monomeric WT CD-BRAF (violet), CD-BRAFD594G (green), and dimeric WT CD-BRAF (blue). The ␣C-helix and activation loop are highlighted with dark blue boxes.
E, the stability of the activation loop for monomeric WT CD-BRAF, CD-BRAFD594G, and dimeric WT CD-BRAF was measured by looking at the root mean square
deviation (RMSD), with respect to the average structure of monomeric WT CD-BRAF (featuring the AS-H1 helix throughout the whole trajectory).

Table 1
Secondary structure analysis of the activation loop
BRAFWT monomer
Residue
Ala-598
Thr-599
Val-600
Lys-601
Ser-602
Arg-603
Trp-604
a
b

310 helix
0.000
0.000
0.006
0.008
0.142
0.142
0.138

BRAFD594G monomera

␣ helix
0.975
0.975
0.986
0.986
0.584
0.445
0.011

310 helix
0.637
0.637
0.637
0.009
0.008
0.008
0.008

␣ helix
0.000
0.000
0.000
0.000
0.000
0.000
0.000

BRAFWT dimerb
310 helix

␣ helix

0.000
0.000
0.000
0.000
0.000
0.008
0.010

0.000
0.000
0.000
0.000
0.000
0.000
0.000

Analysis done on trajectory ⬎240 ns (i.e. ⬎4800 time (⫻50 ps) in Fig. 1E above).
Result of protomer A is shown; result of protomer B is almost identical to A.

As mentioned previously, D594G is commonly found in lung
cancer. To observe what effects lung cancer cells have on heterodimer activity, we performed a similar experiment in HTB-

177 (KRASQ61H) lung cancer cells. For this experiment, we
transfected CRAF, D594G:CRAF, and BRAF:CRAF in HTB177 cells and monitored their activity (Fig. S2). As expected,
J. Biol. Chem. (2020) 295(8) 2407–2420

2409

Oncogenic BRAFD594G reveals kinase-independent function

Figure 2. Heterodimers have stronger dimer interfaces than homodimers. A, CRAF, BRAF:CRAF, and D594G:CRAF were transiently transfected into HEK293
cells, and the lysates were probed for the indicated proteins using immunoblotting. B, CRAF, BRAF:CRAF, and D594G:CRAF co-immunoprecipitated from cell
lysates were incubated with purified MEK1K97M to measure their respective activities by probing for phospho-MEK (pMEK). The Western blots are representative
of three independent replicates. The relative intensity values were calculated in ImageJ and are shown below the blot. The molecular mass values (kDa) above
and below the band are indicated to the left of the blot. C, molecular dynamics trajectory measuring the distance between the conserved Arg residue’s
guanidino C (BRAF:R509/CRAF:R401) and the center of an H-bonding acceptor pocket on the other protomer across the dimer interface BRAF:BRAF (blue),
CRAF:D594G (gold), and CRAF:CRAF (red). H-bonding from protomer A to protomer B is shown at the top, whereas protomer B to A is shown below. D,
representative snapshots of the dimer interfaces of BRAF:BRAF (gray:gray, top), CRAF:D594G (pink:gold, middle), and CRAF:CRAF (pink:pink, bottom). The key
hydrogen bond contacts are emphasized with yellow highlights.

BRAFD594G:CRAF heterodimer activity is similar to that of
BRAF:CRAF. This confirms that activity of BRAF is expendable
for activation of CRAF. Additionally, the elevated activity in the
presence of heterodimers establishes the necessary signaling
output for transformation in cancer cells.
To understand why the BRAF:CRAF heterodimer forms
readily, we applied MD simulations to investigate the atomistic
details of BRAF:CRAF heterodimerization. We started with the
dimeric CRAF (PDB entry 3OMV (6)) and dimeric BRAF (PDB
entry 4E26 (16)) crystal structures with any bound inhibitors
removed. The BRAFD594G:CRAF heterodimer is constructed by
replacing one protomer of the BRAF dimer with a CRAF
protomer (extracted from the CRAF dimer structure) via alignment between the incoming and outgoing protomer, as well as
introduction of D594G mutation to the remaining BRAF
protomer. The production simulations of BRAF:BRAF,
BRAFD594G:CRAF, and CRAF:CRAF were carried out for 200 –
300 ns. By comparing the gain or loss and the strength of
H-bonds, we conclude that BRAF:CRAF heterodimers are
thermodynamically more stable than the corresponding
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homodimers. The interprotomer interaction can be illustrated
by analyzing the distance between BRAF:CRAF Arg-509/Arg401 (H-bond donors) and their corresponding H-bonding partners on the other protomer (Fig. 2, C and D). The calculated
distance (⬃3 Å) for BRAF:CRAF and BRAF:CRAF dimers is
ideal for H-bond formation between two protomers, but not for
CRAF:CRAF dimer. In addition to the Arg-509 H-bonds,
BRAFD594G:CRAF heterodimers have strong interprotomer
interactions between the following donor/acceptor pairs: His510/His-369, His-402/His-477, and Arg-398/Asp-448. The
average number of H-bonds (Table 2) is the sum of the fraction
of H-bonds that occur in the simulations during a period of
150 –200 ns. Thus, the BRAFD594G:CRAF heterodimer forms
the strongest dimer, followed by BRAF:BRAF, and the CRAF:
CRAF homodimer is the weakest of the three.
Together, the increased dimerization potential of the heterodimer is reflected by the increased BRAF:CRAF heterodimer activity in cellulo and in vitro. CRAF homodimer
forms the weakest dimer, reinforcing the notion that CRAF has
the lowest basal activity alone.

Oncogenic BRAFD594G reveals kinase-independent function
Table 2
Strength of key hydrogen bond interactions
H-bond donora
A-Arg-509
B-Arg-509
A-Arg-509
B-Arg-509
A-His-510
B-His-510
A-Arg-506
B-Arg-506

b

H-bond acceptora
B-Thr-508/Arg-506/Leu-505
A-Thr-508/Arg-506/Leu-505
B-Phe-516
A-Phe-516
B-His-477
A-His-477
B-Asp-448
A-Asp-448

Average number of H-bonds
a
b

WT BRAF dimer

CRAF-BRAFD594G

CRAF dimer

1.51
1.69
0.69
0.12
0.84
0.97
0.00
1.33

1.60
1.66
0.98
0.00
0.84
0.95
2.00
0.00

0.00
0.00
0.00
0.99
0.32
0.00
0.00
0.00

7.15

8.03

1.31

H-bond donors are guanidino NH in Arg or NH in His; H-bond acceptors are carbonyl oxygens or carboxylate oxygens in Asp-448.
BRAF(CRAF) residue ID equivalency: Arg-509(Arg-401), Thr-508/Arg-506/Leu-505(Thr-400/Arg-398/Leu-397), His-510(His-402), His-477(His-369), Asp-448(Tyr-340).

The stability of BRAFD594G:CRAF heterodimers is
14-3-3– dependent
The formation of BRAF:CRAF heterodimers occurs in normal cells through RAS-induced membrane recruitment (5, 6,
18, 19). The factors promoting dimerization of oncogenic
BRAFD594G:CRAF remain controversial. In light of this, we created a series of BRAFD594G truncation constructs: ⌬N-tail
(region containing the BRAF-specific region), ⌬RAS-binding
domain (⌬RBD), ⌬CR2, and ⌬SSDD by truncating from the
N-terminal toward the kinase domain to identify which regions
of BRAFD594G are crucial for dimerization with CRAF (Fig. 3A).
We transiently transfected the BRAFD594G deletion constructs:
⌬N-tail, ⌬RAS-binding domain (⌬RBD), ⌬CR2, and ⌬SSDD
into HEK293 cells with or without WT CRAF (Fig. 3B). The
BRAFD594G constructs and CRAF have poor expression as single transfections, but when co-transfected together, the expression increases on average 9- and 2-fold for BRAFD594G and
CRAF, respectively, suggesting that formation of BRAFD594G:
CRAF protects both proteins from degradation. The observed
change in expression of both BRAF and CRAF can be used as a
tool to determine whether heterodimer pairs form in cells. All
of the BRAFD594G constructs containing the SSDD motif were
able to stabilize CRAF (Fig. 3B). It is not surprising that ⌬SSDD
lost the ability to activate CRAF, as the SSDD motif is important
for proper regulatory spine alignment, which is a prerequisite
for dimerization and activation of RAF family members (13).
14-3-3 chaperone protein binding to pSer-729 of BRAF
enhances homo- or heterodimerization of WT RAF (20, 21).
AMPK has been identified to phosphorylate the BRAF C-terminal 14-3-3– binding site, Ser-729 (21). To verify the effect of
14-3-3 on BRAFD594G:CRAF dimerization, we treated cells
expressing RAF heterodimers with dorsomorphin 2HCl (compound C), a potent AMPK inhibitor. The phosphorylation of
Raptor, a well-established protein substrate of AMPK, was
decreased in the presence of compound C, verifying that AMPK
is potently inhibited (Fig. 3C). Additionally, total CRAF,
pCRAF, and pSer-729 were decreased in the context of the
BRAFD594G:CRAF heterodimer (Fig. 3C). To further verify
the role of 14-3-3 binding, we introduced the S729A mutation
to mimic unphosphorylated BRAFD594G. Unfortunately,
BRAFD594G/S729A was not expressed well in HEK293 cells, preventing more detailed investigation. This is consistent with the
findings of Park et al. (22), who show that the mutation to
S729A results in poor stability of purified BRAF from insect or
mammalian cells. Regardless, the observed destabilization by

the S729A mutation together with the compound C data suggest that 14-3-3 binding to pSer-729 stimulates BRAFD594G:
CRAF heterodimerization and subsequent CRAF activation.
Because phosphorylation of Ser-729 was not completely
depleted by the AMPK inhibitor, these results suggest that
there are other kinases, other than AMPK, that are responsible
for Ser-729 phosphorylation. In parallel, AMPK inhibitor has
little effect on pSer-729 and pCRAF-Ser-338 in the context of
WT BRAF:CRAF heterodimers, suggesting that they have a distinct regulation mechanism.
BRAFD594G:CRAF heterodimers bypass autoinhibitory phosphorylation in cancer cells
We previously identified that BRAFWT can autophosphorylate its P-loop (Ser-465/Ser-467) to inactivate itself in the
absence of native substrate MEK (15). By doing so, BRAF is
subject to fine-tuned regulation to ensure rapid termination of
RAF signaling. To determine whether BRAF:CRAF and
BRAFD594G:CRAF use a similar mechanism, we incubated these
kinases with ATP for 30 min to let autophosphorylation complete prior to quantifying their specific activity. The activity of
BRAF:CRAF was decreased by ⬃40 –50% upon autophosphorylation (Fig. 4A), suggesting that autophosphorylation of certain residues negatively regulates the kinase activity of BRAF.
Intriguingly, no obvious change was detected for BRAFD594G:
CRAF (Fig. 4A), demonstrating that oncogenic mutations can
bypass autophosphorylation to sustain pathway signaling. To
further verify this finding, we monitored total BRAF autophosphorylation via 32P autoradiograph. As shown in Fig. 4B,
BRAFWT was able to autophosphorylate itself and MEK; however,
BRAFD594G:CRAF could only phosphorylate BRAFD594G and
MEK, and not CRAF (Fig. 4B). The lack of CRAF phosphorylation
within BRAFD594G:CRAF dimers provides compelling evidence
that RAF autophosphorylation occurs in trans, not in cis.
To further verify this model, we introduced the R509H mutation, a mutation known to disrupt the “side-to-side” dimer interface of BRAF, to BRAFV600E. As monomeric BRAFV600E/R509H is
still active, our data clearly demonstrate that autophosphorylation requires an intact dimer interface and occurs as transrather than cis-autophosphorylation (Fig. 4, A and B). Our
finding highlights the physiological significance of the “side-toside” dimer interface, other than allosteric trans-activation.
Within a BRAF dimer, BRAF trans-phosphorylates both activation loop and inhibitory phosphorylation sites to fine-tune
the overall BRAF activity (Fig. 4, A and B) (15, 17).
J. Biol. Chem. (2020) 295(8) 2407–2420
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Figure 3. The stability of BRAFD594G and CRAF is dependent on heterodimerization. A, schematic diagram of the deletion mutants of BRAFD594G. In
FL-D594G, the conserved regions (CR1–3) and specific motifs are labeled. The amino acid numbers are identified for the beginning/end of the construct and
conserved regions. The RAS-binding domain (RBD), cysteine-rich domain (CRD), serine/threonine-rich domain (S/T Rich), SSDD (aa 446 – 449), and kinase
domain are labeled accordingly. B, the indicated constructs were transiently transfected into HEK293 cells. We examined the expression changes of D594G in
the presence and absence of CRAF in cells cultured under 10% fetal bovine serum. A scatter plot is shown with the individual points and the average ⫾ S.D.
(error bars). The relative expression level of CRAF indicates CRAF expression alone or in the presence of WT BRAF or D594G constructs that are all normalized
to FL-BRAFD594G. C, 5 M compound C, an AMPK inhibitor (AMPKi), was added to HEK293 cells expressing either BRAF:CRAF or D594G:CRAF for 4 h. ImageJ was
used to calculate the relative intensity values, which are shown below the blot. The molecular mass values (kDa) are shown to the left of the blot.

P-loop phosphorylation destabilizes BRAF dimers
Our mechanistic studies identified that P-loop phosphorylation negatively regulates the kinase activity of BRAFWT (17).
We carried out MD simulations on dimeric BRAFWT kinase
domain with P-loop phosphorylation (pSer-465/pSer-467) and
compared it with the simulations of WT unphosphorylated
dimer. Both simulations started from the same crystal structure
(PDB entry 4E26 (16)). Our MD data demonstrate that phosphorylation of the P-loop disfavors dimer formation by disrupting multiple H-bonds in the dimer interface, whereas these
H-bonds remained intact in the unphosphorylated dimer (Fig.
4C). In addition, the two phosphorylated protomers also moved
apart from each other (black trajectory, Fig. 4C), relative to the
unphosphorylated protomers (blue trajectory, Fig. 4C), further
validating the distorted dimer configuration. Other dimer simulations, including WT dimer and P-loop phosphorylation with
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inhibitors and WT dimer with the R509H mutation, show consistent results of weakened dimeric interaction upon P-loop
phosphorylation or introduction of the R509H mutation (Fig.
S3). Consistent with our MD simulations, co-immunoprecipitation experiments verified that introduction of the phosphomimetic mutation S465D/S467D (SS/DD) to the P-loop compromised the dimerization ability of BRAF, as shown in Fig. 4D.
Together, we conclude that P-loop phosphorylation decreases the
formation of BRAF dimers and most likely displaces the ␣C-helix
to an OUT position that leads to an inactive conformation.
Inhibiting the catalytic activity of CRAF within the
BRAFD594G:CRAF
The two FDA-approved BRAF drugs dabrafenib and vemurafenib have a positive clinical outcome for patients harboring
oncogenic BRAFV600E, but are less effective toward non-Val-
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Figure 4. Inhibitory autophosphorylation of the P-loop disrupts dimerization of WT BRAF and is bypassed by BRAFD594G:CRAF heterodimers. A, WT
BRAF, BRAFV600E/R509H, BRAF:CRAF, and D594G:CRAF were preincubated with ATP (⫹) or without ATP (⫺) for 30 min at room temperature to allow the
completion of autophosphorylation and then were incubated with MEK1K97M for 10 min at 30 °C. The relative kinase activities of unphosphorylated RAF protein
(Native) and autophosphorylated RAF protein (Auto) were quantified to the respective native lanes of three independent experiments ⫾ S.D. (error bars) and
are shown below the immunoblots. A scatter plot is shown of the relative kinase activity of the autophosphorylated lanes normalized to the respective native
lane. B, 32P-labeled ATP was incubated with WT BRAF, BRAFV600E/R509H, and D594G:CRAF in the presence and absence of MEK1K97M for 30 min before being
subjected to SDS-PAGE radiograph gel imaging. Autophosphorylation of RAF and phosphorylation of MEK1K97M were recorded simultaneously. C, molecular
dynamics simulations monitoring the protomer distance of WT BRAF or P-loop phosphorylated BRAF (pSer-465/pSer-467) were examined. The trajectory of the
dimer interface was tracked for WT BRAF (blue) and pSer-465/pSer-467-BRAF (black). Snapshots showing the dimer interface for WT BRAF (top) and pSer-465/
pSer-467-BRAF (bottom) are shown to the right. Hydrogen-bonding interactions are indicated by yellow circles. D, WT BRAF (BRAFWT) and BRAF S465D/S467D
(BRAFSS/DD) were transiently transfected into HEK293 cells. FLAG-tagged BRAF was co-immunoprecipitated from the cell lysate and then probed for V5-tagged
BRAF. The ratio of V5 to FLAG is shown to the right of the immunoblots for three independent experiments ⫾ S.D. The relative intensity values are below the
blot. The molecular mass standard values (kDa) are identified to the left of the blot.

600 BRAF mutants (4, 9). Other laboratories have suggested
that targeting MEK or EGFR is a viable treatment option for
class 3 BRAF tumors (8), but currently no RAF directed therapies are available. There are three types of BRAF inhibitors,
which are grouped by how they orient the ␣C-helix or DFG
motif (4). Type I inhibitors, such as SB-590885 (SB), lock BRAF
into an active conformation with ␣C-helix-IN and DFG-IN.
Type I1⁄2 inhibitors, including dabrafenib, vemurafenib, PLX4720, and PB-PLX7904 (PB), orient the ␣C-helix-OUT and
DFG-IN conformation. Type II inhibitors, such as AZ-628
(AZ), adopt the ␣C-helix-IN and DFG-OUT conformation.
The ␣C-helix-IN (type I/II) configuration allows for inhibitor
binding to both protomers of BRAF with equal potency;
however, type I1⁄2 inhibitors lock the ␣C-helix-OUT configuration to sterically hinder occupancy for the second
protomer, which leads to negative cooperativity. Although
each category of inhibitor is effective at inhibiting
BRAFV600E (17), they have very different binding mechanisms that regulate dimeric WT BRAF differently. WT BRAF

displays drug resistance and paradoxical activation toward
1
type I ⁄2 inhibitors.
Here we evaluate the different categories of RAF inhibitors
against BRAFD594G:CRAF heterodimers. Differential scanning
fluorimetry (DSF) results show that all of the tested ATP-competitive inhibitors bind to CD-BRAFD594G (Fig. 5A), although
BRAFD594G could not bind to ATP (Fig. S1). However, it
remains unclear whether these inhibitors can trigger paradoxical activation in cells expressing BRAFD594G. Additionally, our
MD simulations have shown that the D594G:CRAF heterodimer is in a different conformation than the CRAF
homodimer; therefore, different drug response is expected
between RAF homo- and heterodimers. To address these concerns, we applied cell-based assays to evaluate the potency of
the selected inhibitors in HEK293 cells transiently transfected
with BRAFD594G and CRAF. BRAFV600E and WT BRAF/CRAF
were used as the controls (Fig. 5, B and C).
Pan-RAF inhibitors, such as AZ, are active against ARAF,
BRAF, and CRAF with equal potency; thus, titrating different
J. Biol. Chem. (2020) 295(8) 2407–2420
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Figure 5. Targeting BRAFD594G:CRAF heterodimers with ATP-competitive inhibitors displays drug resistance despite decreased MAPK signaling. A, 5
M CD-D594G was incubated with 25 M inhibitor and then subjected to DSF. The melting temperatures (Tm) of CD-D594G with DMSO, dabrafenib, AZ-628,
PLX-4720, PB, and SB-590885 were plotted. The ⌬Tm was calculated by subtracting CD-D594G in the presence of drug from no treatment. B and G, the
respective constructs were transiently transfected into HEK293 cells and treated with inhibitor at the indicated drug concentrations for 1 h. B and C, BRAFV600E
and BRAF:CRAF were treated with dabrafenib. D–G, D594G:CRAF was treated with AZ-628 (D), PB (E), SB-590885 (F), and PLX-4720 (G). H, D594G:CRAF was
treated with the specified drug for 1 h before lysing and then co-immunoprecipitation with anti-FLAG resin. I and J, BRAFS465A/S467A (I) and D594G:CRAF (J) were
treated with dabrafenib in HEK293 cells. K and L, melanoma cells, WM3629, expressing BRAFD594G and NRASG12D were treated with AZ-628 for 1 h for Western
blot analysis (K) or 96 h for cell viability experiments (L). Cell viability was calculated by dividing the A450 (absorbance for the WST reagent) with AZ-628
treatment by the A450 for no treatment ⫻ 100. The cells were harvested and lysed with 4% SDS and then subjected to Western blotting analyses, unless
otherwise indicated. The relative intensities are shown below the blot. The molecular mass numbers (kDa) are identified to the left of the blot. Error bars, S.D.

concentrations of AZ showed inhibition at 0.1 M (Fig. 5D).
The potency of AZ toward BRAFD594G:CRAF is not surprising,
because this inhibitor has been shown to have low nanomolar
potency toward CRAF in cell-free experiments (23). Additionally, Noeparast et al. (24) show a similar inhibition profile
toward the D594G:CRAF heterodimer. PB is a paradox-breaking inhibitor designed to minimize paradoxical activation (25),
but type I1⁄2 inhibitors have much lower activity toward dimeric
RAF, and no significant activity of PB toward the BRAFD594G:
CRAF heterodimer was observed (Fig. 5E). Although AZ and SB
target monomeric and dimeric BRAF with similar potency, SB
only shows inhibition at the highest concentration tested
toward BRAFD594G:CRAF (Fig. 5, D and F), most likely due to its
low potency toward CRAF. We also tested PLX-4720, which is
known to potently inhibit monomeric BRAF, and it only shows
slight inhibition of the BRAFD594G:CRAF heterodimer at the
highest concentration of drug used (Fig. 5G). AZ, a representative of type II pan-RAF inhibitors, exhibits inhibition of the
BRAFD594G:CRAF heterodimer at the lowest concentrations
tested. Additionally, Karoulia et al. (4) have identified that panRAF inhibitors have a slower off rate and dissociate the RAF/
MEK complex. These data suggest that pan-RAF inhibitors
might be a good scaffold for rationally designed BRAFD594G:
CRAF inhibitors.
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Notably, none of the ATP-competitive inhibitors induced
paradoxical activation even though binding of the DFG-IN
inhibitors dabrafenib, PLX-4720, and SB shows slight enhancement of BRAFD594G:CRAF heterodimerization (Fig. 5H). On
the contrary, WT BRAF:CRAF heterodimers were paradoxically activated by dabrafenib under the same conditions (Fig.
5C) (24). Due to the correlation of BRAFD594G and P-loop autoinhibitory phosphorylation, we introduced an S465A/S467A
(SS/AA) mutation to WT BRAF to prevent P-loop phosphorylation. No paradoxical activation was observed for BRAFSS/AA,
suggesting that P-loop phosphorylation plays a role in paradoxical activation (Fig. 5I). Under this scenario, kinase-dead BRAF
abolishes P-loop phosphorylation of catalytically active CRAF
within the BRAFD594G:CRAF dimer, which also evades paradoxical activation. This model is consistent with the work of
Holderfield et al. (26), who highlighted that ATP-competitive
inhibitor relieves inhibitory P-loop phosphorylation of WT
RAF to trigger paradoxical activation. Another possibility is
that the BRAFD594G mutation already makes BRAF a perfect
allosteric activator and inhibitor binding makes no further
enhancement regarding its ability to transactivate CRAF (Fig.
5J).
We also treated melanoma cells (WM3629) that express
BRAFD594G and NRASG12D with AZ (Fig. 5K). The pan-RAF
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Figure 6. Targeting the dimer interface of BRAFD594G:CRAF heterodimers causes both protein degradation and diminished MAPK signaling in cells.
A, D594G:CRAF were transiently transfected and then treated with TAT-Braftide (0, 10, 25, 50, 75, and 100 M) for 4 h. B, melanoma cells, WM3629, harboring
BRAFD594G and NRASG12D were treated with TAT-Braftide for 4 h. The cells were harvested and lysed with 4% SDS and then subjected to Western blotting
analyses. C, WM3629 were treated with TAT-Braftide for 48 h, and then the medium was replaced with WST reagent diluted in Opti-MEM. Percentage cell
viability was calculated by dividing the A450 with Braftide by the A450 for no treatment ⫻ 100. The relative intensities of the bands are located below the blot.
The molecular mass values (kDa) are located to the left of the blot. Error bars, S.D.

inhibitor completely abolished MEK/ERK signaling at 1 M,
which indicates that AZ can inhibit the MAPK pathway in a
short time period. However, long exposure of 96 h still exhibited ⬃50% of cell growth at the highest concentration (5 M) of
drug treated (Fig. 5L), suggesting that BRAFD594G:CRAF heterodimers display drug resistance toward ATP-competitive
inhibitors. This is consistent with another group who showed
that AZ alone cannot fully eliminate growth of cells harboring
various RAS mutations (27). The discrepancy between the
amount of drug required for MAPK inhibition and cancer cell
death highlights that pan-RAF inhibitors might not be a viable
therapeutic treatment for class 3 BRAF mutations.
RAF dimer breaker is active against BRAFD594G:CRAF
Recognizing that dimerization of BRAFD594G and CRAF is
critical for both protein stability and kinase activity poises the
dimer interface as a promising drug target. Previously, we
developed a 10-mer peptide (Braftide) that shows efficient inhibition and degradation of WT BRAF and BRAFG469A both in
vitro and in a variety of cells exhibiting either RAS dependence
or independence, respectively (28). To extend the same study to
BRAFD594G:CRAF heterodimers, we titrated 0 –100 M TATBraftide into HEK293 cells overexpressing the BRAFD594G:
CRAF heterodimer (Fig. 6A). This peptide inhibitor shows not
only inhibition of MAPK signaling, but also degradation of the
BRAFD594G:CRAF heterodimer at as low as 25 M. We applied
a similar experiment to WM3629 cancer cells (Fig. 6B). TATBraftide exhibits degradation of BRAFD594G and CRAF at concentrations as low as 2.5 M in WM3629 cells. We treated
WM3629 cells with TAT-Braftide for 48 h to observe the activity of this peptide by cell viability assays, which showed dosedependent inhibition of cell growth and an EC50 of 11.05 ⫾ 1.12
M (Fig. 6C). Together, these results highlight that BRAFD594G:
CRAF heterodimers are still sensitive to dimer breakers, despite
the fact that it has a stronger dimer interface than BRAF
homodimers.

Discussion
In our study, we focused on BRAFD594G, a representative of
kinase-dead BRAF mutants, to better understand the noncatalytic function of BRAF. Interestingly, protein kinases have
evolved to have allosteric scaffolding properties, in addition to
their inherent capability of catalyzing the transfer of the
␥-phosphate from ATP to tyrosine, serine, or threonine residues in the substrate proteins. Pseudokinases are an example of
enzymes that have diverged to primarily function as scaffolds,
such as kinase-impaired HER3 which allosterically activate
other EGFR/HER family members through asymmetric
dimerization (29). Another example is kinase-suppressor of
RAS (KSR) which has been shown to function as a scaffolding
protein to allosterically regulate RAF and MEK (30). BRAF
kinase has both scaffold function and catalytic activity that are
integrated to determine the final output of RAF signaling.
Intriguingly, ATP-competitive inhibitors can differentially
alter the two functions to trigger paradoxical activation, in
which the scaffold function of BRAF is exaggerated to compensate the inhibited kinase activity, and the overall outcome is
enhanced RAF signaling. However, it is hard to pinpoint which
role is more significant than the other. The kinase-dead BRAF
mutant provides a valuable tool to elucidate the allosteric consequence of mutations that are linked to cancer.
Our biophysical experiments and MD simulations show that
BRAFD594G is more prone to dimerization than BRAFWT due to
the positioning of the ␣C-helix toward the IN conformation. In
addition, the activation loop of BRAFD594G is beginning to
unwind from the AS-H1 loop toward full extension, which is a
prerequisite for kinase activation. The extended activation loop
stabilizes the regulatory spine (R-spine) and ␣C-helix into a
conformation suitable for dimerization (30); thus, BRAFD594G
is in a partially active, dimerization-competent conformation
leading to enhanced allosteric function. Interestingly, the most
recent cryo-EM structure of BRAF in complex with ATP analog
J. Biol. Chem. (2020) 295(8) 2407–2420

2415

Oncogenic BRAFD594G reveals kinase-independent function
ATP␥S suggests that ATP binding is critical to maintain the
autoinhibited state (22). Because BRAFD594G cannot bind ATP,
this feature further stabilizes the active conformation of BRAF
to support RAF dimerization.
Experiments with other pseudokinases (VRK, MLKL,
STRAD, ERBB3, and JAK2) have emphasized that ATP binding
can enhance allosteric activation of the associated partner for
some pseudokinases (31–34). However, BRAFD594G does not
bind ATP but still functions as an allosteric activator. In addition, the A481F or A373F mutations, which interfere with ATP
binding to BRAF or CRAF, respectively, have been shown to
constitutively dimerize with and activate the RAF binding partner (35). These results combined with ours suggests that the
alignment of the catalytic spine is not necessary for the scaffold
function of BRAF.
Enhanced signaling required to drive MAPK pathway activation in cells is attained by either increased enzyme activity or
reduced negative regulatory feedback effects (36). We show
that BRAFD594G:CRAF heterodimers are more active than
CRAF alone and have an activity that is comparable with that of
the BRAF:CRAF heterodimer. This increase in activity could be
attributed to BRAFD594G:CRAF heterodimers bypassing inhibitory P-loop autophosphorylation that negatively controls WT
RAF activity in cells (17). The glycine-rich P-loop (Gly-X-GlyX-X-Gly motif) is highly conserved among protein kinases and
is known to position the ␣-/␤-phosphates of ATP for optimal
␥-phosphoryl transfer during catalysis. In addition, it is
believed that the hydrophobic interactions between P-loop and
activation loop stabilize the inactive configuration of the kinase
(37). Protein kinases share a universal activation mechanism, in
which conformational changes in three conserved structural
motifs at the active site (the activation loop, the DFG motif, and
the ␣C-helix) determine the transition from the inactive to the
active conformation (38). The effect of P-loop phosphorylation
has not been well-studied. Our MD simulation results demonstrate that phosphorylated P-loop disfavors the side-to-side
dimer configuration, which in turn supports the nonproductive
position of the ␣C-helix. Here, we have confirmed the existence
of a cross-talk among the P-loop and the three motifs that modulates the conformational equilibrium of the BRAF kinase.
These data unveil P-loop as an important structural feature
involved in positioning the ␣C-helix, depending on its phosphorylation status. Given that the Ser-465/Ser-467 residues are
highly conserved among the P-loop (Fig. S4, A and B), it is
appealing to propose a similar role for the conserved Ser/Thr
residues in other kinase families.
Previously, the molecular mechanism of RAF regulation has
been mostly derived from structures of isolated kinase domains
or fragments of other domains. The cryo-EM structures of fulllength BRAF-MEK1–14-3-3 complexes were solved recently
(22), providing a more comprehensive structural characterization of RAF. In those structures, both autoinhibited and fully
activated BRAF were captured, demonstrating that MEK1 and
14-3-3 are both involved in stabilizing BRAF in the active or
inactive conformations (22). Our findings introduce an additional layer of complexity to the precise mechanism of BRAF
activation. Our laboratory previously identified that the presence of MEK1 decreases overall BRAF autophosphorylation

2416 J. Biol. Chem. (2020) 295(8) 2407–2420

Figure 7. Stepwise activation of BRAF under physiological conditions. i,
monomeric BRAF is found in the cytosol with the N-terminal and C-terminal
interaction causing BRAF to be inactive. ii, active RAS stimulates the N-terminal domain of BRAF to release from the C-terminal domain. iii, RAS clustering
brings RAF monomers in close proximity, which promotes RAF dimerization.
iv, BRAF is stabilized by MEK that helps facilitate autophosphorylation of the
activation loop (red). After MEK phosphorylation, BRAF and MEK dissociate,
allowing active MEK to interact with ERK. v, BRAF regulates its activity by
autophosphorylating the P-loop (Ser-465/Ser-467, violet), leading to inactive
BRAF. vi, P-loop phosphorylation renders BRAF inactive, down-regulating the
entire MAPK signaling cascade. The inactive kinases are shown in gray,
whereas the active kinases are indicated by blue. RBD, RAS-binding domain;
NTA, N-terminal acidic domain.

while increasing phosphorylation of the activation loop in vitro,
suggesting a new allosteric role of MEK1, other than functioning as a substrate of RAF kinases (15). In light of those findings,
we propose one model for RAF regulation under physiological
conditions, as shown in Fig. 7. After RAS-initiated RAF
dimerization, MEK binding primes the activation loop of RAF
for trans-phosphorylation (15), which leads to maximal RAF activation and subsequent MEK phosphorylation.
Upon dissociation of phosphorylated MEK, RAF trans-phosphorylates the P-loop to diminish its own kinase activity. Meanwhile, this negative regulation loop can be dampened by protein
phosphatases to maintain the highest RAF activity. In this
model, P-loop autophosphorylation is a self-sustained mechanism to self-limit its kinase activity in vivo.
Two main models have emerged to shed light on the molecular mechanism of paradoxical activation. The first model suggests that binding of RAF inhibitors increases dimerization of
drug-bound RAF with inhibitor-free RAF, which results in
RAS-dependent MEK/ERK activation (5). Similarly, Heidorn et
al. (12) have related this model to how kinase-dead BRAF activates CRAF in a RAS-dependent manner. The second model
identifies that RAF inhibitors activate MEK/ERK by relieving
inhibitory RAF autophosphorylation (26). In our work, we provide evidence reconciling the two models of paradoxical activation. We show that inhibitory autophosphorylation occurs in
trans, not in cis; thus, oncogenic BRAFD594G can evade this
negative feedback loop by eliminating autophosphorylation of
CRAF in the BRAFD594G:CRAF heterodimer due to the lack of
enzyme activity. RAF ATP-competitive inhibitors do not dis-
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play paradoxical activation in the context of BRAFD594G:CRAF
heterodimer, providing direct evidence that relief of P-loop
phosphorylation by RAF inhibitors is capable of activating
MAPK signaling. Additionally, BRAFD594G and CRAF readily
form a stable dimer; hence, RAF inhibitors could no longer
boost the allosteric function of BRAF.
The increased frequency of non-Val-600 mutations detected
in lung and other cancers highlights the urgency of targeting
class 3 BRAF (39). Although there have been several proposed
strategies to combat dimer-dependent BRAF mutations, such
as targeting CRAF, MEK, and EGFR (3, 9, 24), there are currently no clinically approved drugs that are designed specifically to treat tumors harboring class 3 BRAF mutations. Since
the approval of targeting BRAFV600E mutations with vemurafenib or dabrafenib in combination with MEK inhibitors, this
has been a suggested strategy to treat other BRAF mutations.
Combination therapy with RAF and MEK inhibitors in cell lines
harboring class 3 BRAF mutations has been analyzed previously
(8, 24). These experiments show that MEK inhibitors alone or
in combination with RAF inhibitors decrease MAPK pathway
activation and induce cellular apoptosis. Although treatment
with MEK inhibitors is promising, cytotoxicity is an inevitable
concern; thus, more specific inhibitors are urgently needed.
Our results on inhibiting phosphorylation of Ser-729 of BRAF
make the C-terminal 14-3-3 binding site a druggable target for
class 3 BRAF mutations. Similarly, Kondo et al. identified that
targeting the ␣I-helix, at the 14-3-3– binding interface, could
have improved therapeutic efficacy in dimer-dependent BRAF
mutations (40).
Braftide activity toward BRAFD594G:CRAF heterodimers in
cells suggests that allosteric inhibitors targeting the dimer
interface could have an improved therapeutic index. In addition, we show that pan-RAF ATP-competitive inhibitors show
initial inhibition of BRAFD594G:CRAF heterodimer activity, but
prolonged exposure fails to abolish WM3629 cancer cell
growth. Moreover, Montagut et al. (41) suggest that overexpression of CRAF, as we see with the co-transfection of
BRAFD594G:CRAF, can lead to acquired resistance to pan-RAF
inhibitors, suggesting that targeting the ATP-binding pocket of
CRAF alone might not be the best therapeutic strategy. Hence,
rationally designed drugs with improved selectivity are
required to target CRAF or the dimer interface for class 3 BRAF
mutations.
Altogether, our work complements the current understanding of kinase-impaired/kinase-dead BRAF mutations, while
highlighting key biochemical properties of the most common
kinase-dead mutation, BRAFD594G. These results identify how
BRAFD594G:CRAF heterodimers sustain increased MEK/ERK
activation in cancer cells, while exposing a new allosteric site, at
the dimer interface, to target class 3 BRAF mutations.

Experimental procedures
Compounds and reagents
Dabrafenib, AZ-628, PLX-4720, PB, SB-590885, and dorsomorphin (compound C) 2HCl were purchased from Selleckchem. 10 mM inhibitor stocks were made in DMSO (RAF inhibitors)/double-distilled water (AMPKi) and stored at ⫺20 °C.

[␥-32P]ATP (#NEG002Z250UC) was purchased from PerkinElmer Life Sciences. Polyethyleneimine hydrochloride-MAX
(PEI-MAX) was purchased from Polysciences (#24765). Fetal
bovine serum was purchased from Gemini Bio-Products (#100602). L-Glutamine (#25030-081), Dulbecco’s modified Eagle’s
medium (DMEM, #11995-065), trypsin-EDTA (#25300-054),
Opti-MEM (#31985-070), and PBS (#10010-023) were purchased from Gibco. SYPRO Orange dye (#S6651) was purchased from Invitrogen. Braftide was synthesized as described
previously (28). All other reagents were purchased without further purification.
Antibodies
Anti-FLAG M2 mouse (#F1804), anti-FLAG M2 rabbit
(#F2555), anti-FLAG M2 magnetic resin (#M8823), and pCRAF
(pSer-338) antibody (#05-538) were purchased from Sigma–
Aldrich. HA antibody (#26183) was purchased from Invitrogen.
Profinity IMAC Ni charged resin (#156-0131) was purchased
from Bio-Rad. Anti-p-MEK1/2 Ser-217/221 (#9154), antipERK1/2 (#4370), anti-BRAF (#14814), anti-CRAF (#9422),
Raptor (#2280), and phospho-Raptor (#89146) were purchased
from Cell Signaling. Actin antibody was purchased from Sigma
(#A2228). Phospho-BRAF (pSer-729) antibody (#ab124794)
was purchased from Abcam.
Plasmids
WT BRAF/6x-HIS/FLAG and CRAF/6x-HIS/HA were
designed as described previously (15). BRAF-D594G/6x-HIS/
FLAG, BRAF-D594G⌬N-tail/FLAG, BRAF-D594G⌬RBD/
FLAG, BRAF-D594G⌬CR2/FLAG, BRAF-D594G⌬SSDD/FLAG,
BRAF-S465D/S467D/6x-HIS/FLAG, and CRAF/FLAG/MBP
were created using common cloning procedures with
pCDNATM 4/TO (Invitrogen) as the vector. WT CD-BRAF
with 16 mutations was a gift from Dr. Ronen Marmorstein’s
laboratory (42), and WT CD-BRAF (aa 442–723), with the
SSDD motif added, was inserted into pET-21(⫹) vector
(Sigma–Aldrich). CD-D594G/6x-HIS was generated using
common cloning procedures with pET-21 ⫹ (Sigma–Aldrich)
as the vector.
Cell lines
WM3629 and HTB177 were purchased from Rockland and
HTCC, respectively. HEK293 cells were a gift from Dr. Catherine Moore (University of the Sciences).
CD-BRAF purification
CD-BRAF-6xHIS was transformed into BL21 codon plus
E. coli cells and grown at 37 °C to an optical density of 600 nm of
0.6 – 0.8, and then 1 mM isopropyl 1-thio-␤-D-galactopyranoside was added and the cells were induced at 16 °C with stirring
at 200 rpm. The harvested pellet was resuspended in lysis buffer
(50 mM HEPES buffer, pH 7.4, 250 mM NaCl, 50 mM KCl, 10 mM
imidazole, 10 mM ␤-mercaptoethanol, 10% glycerol, and protease inhibitor tablet (Sigma, catalog no. 11836170001)) and then
lysed with a sonicator. The lysed suspension was centrifuged to
separate the clarified supernatant, and then the supernatant
was applied to pre-equilibrated nickel resin and incubated with
rotation at 4 °C for 1–2 h. After resin incubation, the supernaJ. Biol. Chem. (2020) 295(8) 2407–2420
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tant/resin slurry was added to a gravity column and washed
with wash buffer (50 mM HEPES, pH 7.4, 250 mM NaCl, 10 mM
imidazole, and 10% glycerol). 50 –250 mM imidazole was added
into low-salt buffer (50 mM HEPES, pH 7.4, 250 mM NaCl, and
10% glycerol) to elute the protein, which was pooled and concentrated, using a Millipore concentrator (#UFC803024),
before injecting onto size-exclusion chromatography (column:
Superdex 200 10/300 GL; #28-9909-44). The corresponding
peaks were analyzed with SDS-PAGE and then pooled, concentrated, and aliquoted. These aliquots were flash-frozen in liquid
nitrogen and stored at ⫺80 °C.
Analytical ultracentrifugation
The velocity AUC experiment was performed as described
previously (42). Briefly, 10 –15 M WT CD-BRAF and
CD-D594G were centrifuged at 42,000 r.p.m. for ⬃8 h while
data were collected over the entire time frame. The results were
analyzed with SEDFIT to calculate the continuous c(S) distribution, and data were graphed using Origin.
Molecular dynamics simulations
The molecular dynamics simulations were performed as
described previously (17). In brief, the crystal structures that
were acquired from the respective PDB files were cleaned up
and solvated in a periodic box using TIP3P water molecules.
The ff14SB (43) force field was used on the proteins. GPUimplemented Amber18 was utilized for each MD simulation
(44). All systems were equilibrated using the same protocol for
solvent minimization, heating, and NPT simulation at 1 atmosphere and 300 K. Production runs using the NVT system at 300
K were then applied for 200 – 400 ns per system. The trajectories were then investigated with the cpptraj program in the
Amber18 package for hydrogen bond interactions, distance,
root mean square deviation, etc. as conveyed in the results sections describing Fig. 1, 2 and 4.
Transient transfection into mammalian cells
HEK293 cells were transiently transfected as described previously (17). In brief, 0.5–1 million HEK293 cells were plated
onto 12- or 6-well plates, respectively, and then were incubated
overnight until the cells reached 40 – 60% confluence. DNA
(0.5–2 g) was mixed with PEI-MAX in a 1:3 ratio. DNA:PEIMAX was added to fresh DMEM on the HEK293 cells. The cells
were washed with ice-cold PBS after 24 – 48 h and then lysed in
4% SDS. The harvested lysate was applied to homogenizer columns, and the flow-through protein concentration was analyzed using a BCA kit (Pierce, #23225). 10 – 40 g of lysates
were used for Western blotting analyses.
BRAF:CRAF co-immunoprecipitation
For immunoprecipitation, 5 million HEK293 cells were
plated onto a 10-cm dish and incubated overnight at 37 °C with
5% CO2. Once the cells reached a confluence of 40 – 60%, the
DMEM was aspirated out, and fresh DMEM was added. A total
of 10 g of DNA (5 g ⫹ 5 g for co-transfections) was mixed
with 30 g of PEI-MAX for 25 min and then added to the plated
cells for 48 h at 37 °C with 5% CO2. For inhibitor treatment, the
cells were washed with PBS, and then DMEM containing
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DMSO (0.5% final) or inhibitor was added to the cells and incubated for 1 h at 37 °C with 5% CO2. Cells were washed again
with ice-cold PBS and then lysed in 1 ml of lysis buffer (50 mM
HEPES, pH 7.4, 150 mM NaCl, 0.1% Nonidet P-40 (IGEPAL630), 1 mM EDTA, 5% glycerol, 1 mM phenylmethylsulfonyl
fluoride, 20 mM ␤-glycerolphosphate, 2.5 mM sodium pyrophosphate, and protease inhibitor) for 2 h with rotation at 4 °C.
The lysate was clarified, and 0.5–1 mg of lysate was applied to
10 l of pre-equilibrated amylose or FLAG resin for 2 h with
rotation at 4 °C. The resin was washed 5⫻ (5 min each wash)
with lysis buffer and then resuspended in 2⫻ dilution buffer (25
mM HEPES, pH 7.4, 0.125 mg/ml BSA, and 300 mM NaCl) for
kinase assays or quenched with 4⫻ loading dye to be analyzed
by Western blotting.
Kinase-dead MEK1-K97M purification
Kinase-dead MEK1-K97M/6xHIS/GST protein was purified
from BL21 codon plus E. coli as described previously (15).
Briefly, the cells expressing MEK1 were harvested and then
lysed in lysis buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 10
mM ␤-mercaptoethanol, Sigma–Aldrich CompleteTM EDTAfree protease inhibitor tablets (product #11836170001), 5 mM
imidazole, and 5% glycerol) with sonication (1 mg/ml lysozyme
was used to help with lysis). The supernatant was added to
equilibrated nickel resin and incubated for 2 h. The proteinbound resin was washed with low-salt buffer (20 mM HEPES,
150 mM NaCl, and 5% glycerol). MEK1 was eluted with elution
buffer (150 mM imidazole, 20 mM HEPES, 150 mM NaCl, and 5%
glycerol) and further purified, concentrated to ⬎0.1 mg/ml, and
stored as described above.
Western blotting– based kinase assay
The kinase assay was performed as described previously (17).
In brief, the purified proteins or co-immunoprecipitation products were diluted with 2⫻ dilution buffer and combined with
2⫻ mixture buffer (25 mM HEPES, pH 7.4, 20 mM MgCl2, 1 mM
DTT, 50 mM ␤-glycerolphosphate, 0.2–2 M MEK (0.1–1 M
final), and 2000 M ATP) for 5–10 min, unless another time is
indicated at 30 °C. The reaction was quenched using 4⫻ loading dye and then analyzed by SDS-PAGE immunoblotting. The
nitrocellulose membranes were probed with the suitable primary and secondary antibodies and imaged using fluorescencebased approaches on a GE Typhoon imager. Analyses of the
immunoblots were analyzed using ImageJ software.
In-gel radioactive assay
As described previously (17), purified or co-immunoprecipitated proteins were mixed with a 2⫻ mixture buffer (25 mM
HEPES, pH 7.4, 20 mM MgCl2, 50 mM ␤- glycerolphosphate, 1
mM DTT, 4 mM Na3VO4, 200 M ATP, and 1 Ci of radioactive
ATP). A final concentration of 1.3 M MEK was added into
the mixture buffer for tests that contained MEK and ATP. The
reaction was incubated at 30 min at room temperature before
being transferred to SDS-PAGE, dried, and imaged on a
Typhoon imager.
Differential scanning fluorimetry
CD-D594G aliquots were diluted in DSF buffer (25 mM
HEPES, pH 7.0, 150 mM NaCl) to a concentration of 5 M
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(final). To a 384-well PCR plate (Thermo Scientific, #AB-1384),
15 l of CD-D594G, 4 l of SYPRO Orange (5⫻ final), and 1 l
of inhibitor in DMSO (25 M final) were added. The plate was
sealed with adhesive seal sheets (Thermo Scientific, #AB-1170)
and then spun down and heated from 20 to 95 °C on QuantStudio 7 Flex (Applied Biosystems) with a ramp rate of 0.015 °C/s.
The protein melt curves were produced, and the first derivative
of the curve was used to analyze the data. The data were examined and plotted using Origin.

9.

10.

Cell viability
The cell viability assay was performed as described previously (28). In brief, WM3629 cells were plated onto a 96-well
plate for 24 h before treatment. TAT-Braftide or AZ-628 were
titrated on to the cells at the indicated concentrations for 48 or
96 h, respectively. The drug medium was switched out every
24 h, and then the WST reagent was added, in a 1:10 ratio, and
incubated for 4 h at 37 °C. Absorbance readings were measured
for the plate at 450 nm.
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